← Back to Screener
Intensity Therapeutics, Inc. Common stock (INTS)
Price$3.77
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-70.15%
Price vs S&P 500 (4W)-25.92%
VGM Score13.95
Market Capitalization$10.19M
All Metrics
Book Value / Share (Quarterly)$3.93
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.57
Price vs S&P 500 (YTD)-71.41%
EPS (TTM)$-7.18
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-7.18
EPS (Annual)$-8.56
ROI (Annual)-97.73%
Cash / Share (Quarterly)$4.03
ROA (Last FY)-82.31%
EBITD / Share (TTM)$-6.05
ROE (5Y Avg)-281.35%
Cash Flow / Share (Annual)$-3.66
P/B Ratio1.02x
P/B Ratio (Quarterly)1.50x
Net Income / Employee (Annual)$-2,321,200
Net Interest Coverage (TTM)-93.78x
ROA (TTM)-105.82%
EPS Incl Extra (Annual)$-8.56
Current Ratio (Annual)5.92x
Quick Ratio (Quarterly)4.57x
3-Month Avg Trading Volume0.04M
52-Week Price Return-66.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.16
52-Week High$43.50
EPS Excl Extra (Annual)$-8.56
26-Week Price Return-62.22%
Quick Ratio (Annual)5.55x
13-Week Price Return-51.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.86x
Enterprise Value$-55,400
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.72
3-Month Return Std Dev47.18%
Net Income / Employee (TTM)$-2,138,600
ROE (Last FY)-97.73%
EPS Basic Excl Extra (Annual)$-8.56
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-7.18
ROI (TTM)-136.82%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.39
Price vs S&P 500 (52W)-90.73%
Year-to-Date Return-63.26%
5-Day Price Return-14.12%
EPS Normalized (Annual)$-8.56
ROA (5Y Avg)-213.24%
Month-to-Date Return-14.12%
EBITD / Share (Annual)$-8.83
ROI (5Y Avg)-208.73%
EPS Basic Excl Extra (TTM)$-7.18
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)2.07x
Book Value / Share (Annual)$4.70
Price vs S&P 500 (13W)-59.42%
Beta3.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-136.82%
52-Week Low$3.70
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.96est. -1.11
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.08
4.08
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INTSIntensity Therapeutics, Inc. Common stock | — | — | F | $3.77 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Intensity Therapeutics is a clinical-stage biotech company developing therapies for solid tumors using its proprietary DfuseRx platform. The company's lead candidate, INT230-6, is administered via direct tumor injection to trigger both localized and systemic immune responses that can target non-injected tumors. Intensity is advancing INT230-6 in metastatic and locally advanced cancer settings where current treatment options are limited.